기본 통계
| LEI | 549300KL3IJPHZM2GR04 |
| CIK | 1697532 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Applied Therapeutics, Inc.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| February 13, 2026 |
15-12G As filed with the Securities and Exchange Commission on February 13, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2026 Applied Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or other jurisdiction of incorporation) (Commis |
|
| February 3, 2026 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION APPLIED THERAPEUTICS, INC. EX-3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. FIRST: The name of the corporation is Applied Therapeutics, Inc. (the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808. The name of the registered agent at s |
|
| February 3, 2026 |
As filed with the Securities and Exchange Commission on February 3, 2026 S-8 POS As filed with the Securities and Exchange Commission on February 3, 2026 Registration No. |
|
| February 3, 2026 |
As filed with the Securities and Exchange Commission on February 3, 2026 S-8 POS As filed with the Securities and Exchange Commission on February 3, 2026 Registration No. |
|
| February 3, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) APPLIED THERAPEUTICS, INC. (Name of Subject Company (Issuer)) AT2B, INC. (Offeror) An indirect wholly owned subsidiary of CYCLE GROUP HOLDINGS LIMITED (Parent of Offeror) (Names of Filing Per |
|
| February 3, 2026 |
As filed with the Securities and Exchange Commission on February 3, 2026 S-8 POS As filed with the Securities and Exchange Commission on February 3, 2026 Registration No. |
|
| February 3, 2026 |
As filed with the Securities and Exchange Commission on February 3, 2026 POS AM As filed with the Securities and Exchange Commission on February 3, 2026 Registration No. |
|
| February 3, 2026 |
CONTINGENT VALUE RIGHTS AGREEMENT EX-99.(d)(5) Exhibit (d)(5) Execution Version Confidential CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of February 3, 2026 (this “Agreement”), is entered into by and between Cycle Group Holdings Limited, a private limited company incorporated in England and Wales (“Parent”), and Equiniti Trust Company, LLC, a New York limited liability trust company, as Right |
|
| February 3, 2026 |
As filed with the Securities and Exchange Commission on February 3, 2026 S-8 POS As filed with the Securities and Exchange Commission on February 3, 2026 Registration No. |
|
| February 3, 2026 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Subject Company) APPLIED THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securit |
|
| February 3, 2026 |
SECOND AMENDED AND RESTATED APPLIED THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF APPLIED THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I STOCKHOLDERS 1.1 Place of Meetings. All meetings of stockholders shall be held at such place (if any) within or without the State of Delaware as may be determined from time to time by the Board of Directors of the corporation (the “Board of Directors”) or, if not determined by the |
|
| February 3, 2026 |
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics EX-99.(a)(5)(K) Exhibit (a)(5)(K) Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics CAMBRIDGE, UK and DETROIT, MICHIGAN – 3rd February 2026 – Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company. Applied’s lead drug candidat |
|
| February 3, 2026 |
As filed with the Securities and Exchange Commission on February 3, 2026 POS AM As filed with the Securities and Exchange Commission on February 3, 2026 Registration No. |
|
| January 30, 2026 |
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer EX-99.(a)(5)(J) Exhibit (a)(5)(J) Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer CAMBRIDGE, UK and DETROIT, MICHIGAN – 30th January 2026 – Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purch |
|
| January 30, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) APPLIED THERAPEUTICS, INC. (Name of Subject Company (Issuer)) AT2B, INC. (Offeror) An indirect wholly owned subsidiary of CYCLE GROUP HOLDINGS LIMITED (Parent of Offeror) (Names of Filing Per |
|
| January 30, 2026 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Subject Company) APPLIED THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securit |
|
| January 29, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) APPLIED THERAPEUTICS, INC. (Name of Subject Company (Issuer)) AT2B, INC. (Offeror) An indirect wholly owned subsidiary of CYCLE GROUP HOLDINGS LIMITED (Parent of Offeror) (Names of Filing Per |
|
| January 29, 2026 |
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer EX-99.(a)(5)(I) Exhibit (a)(5)(I) Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer CAMBRIDGE, UK and DETROIT, MICHIGAN – 29th January 2026 – Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purch |
|
| January 29, 2026 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Subject Company) APPLIED THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securit |
|
| January 29, 2026 |
EX-99.(a)(5)(G) Exhibit 99 a(5)(G) Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension NEW YORK, January 29, 2026 – Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter |
|
| January 28, 2026 |
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer EX-99.(a)(5)(H) Exhibit (a)(5)(H) Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer CAMBRIDGE, UK and DETROIT, MICHIGAN – 28th January 2026 – Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purch |
|
| January 28, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) APPLIED THERAPEUTICS, INC. (Name of Subject Company (Issuer)) AT2B, INC. (Offeror) An indirect wholly owned subsidiary of CYCLE GROUP HOLDINGS LIMITED (Parent of Offeror) (Names of Filing Per |
|
| January 28, 2026 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Subject Company) APPLIED THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securit |
|
| January 21, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) APPLIED THERAPEUTICS, INC. (Name of Subject Company (Issuer)) AT2B, INC. (Offeror) An indirect wholly owned subsidiary of CYCLE GROUP HOLDINGS LIMITED (Parent of Offeror) (Names of Filing Per |
|
| January 21, 2026 |
Dear Applied Therapeutics Stockholder: EX-99.(a)(5)(G) Exhibit (a)(5)(G) Dear Applied Therapeutics Stockholder: You should have recently received materials from Cycle Group Holdings Limited related to the offer to purchase (the “Offer”) all of the outstanding shares (the “Shares”) of common stock of Applied Therapeutics, Inc. (“Applied”) at a price of (i) $0.088 per Share, net to the seller in cash, without interest (the “Closing Amoun |
|
| December 29, 2025 |
EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated December 29, 2025, and the related Letter of Transmittal and any amendments or supplements to such Offer to Purchase or Letter of Transmittal, and is being made to a |
|
| December 29, 2025 |
(The remainder of this page is intentionally left blank.) EX-99.(d)(4) Exhibit (d)(4) Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL October 2025 10/30/2025 Cycle Pharmaceuticals Limited 21 JJ Thompson Ave Cambridge CB3 0FA Ladies and Gentlemen: In connection with the consideration of a possible negotiated transaction (the “Transaction”) between Applied Therapeutics, Inc. ( |
|
| December 29, 2025 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of APPLIED THERAPEUTICS, INC. at $0.088 per share, net in cash, plus one non-tradable contingent value right (“CVR”) per share representing the contractual right to receive up to four contingent cash payments of up to an aggregate of $0.40 per CVR upon the achievement of certain specified milestones plus the |
|
| December 29, 2025 |
(The remainder of this page is intentionally left blank.) EX-99.(e)(2) Exhibit (e)(2) Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL October 2025 10/30/2025 Cycle Pharmaceuticals Limited 21 JJ Thompson Ave Cambridge CB3 0FA Ladies and Gentlemen: In connection with the consideration of a possible negotiated transaction (the “Transaction”) between Applied Therapeutics, Inc. ( |
|
| December 29, 2025 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Subject Company (Issuer)) AT2B, INC. (Offeror) An indirect wholly owned subsidiary of CYCLE GROUP HOLDINGS LIMITED (Parent of Offeror) (Names of Filing Persons (identifying st |
|
| December 29, 2025 |
EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of APPLIED THERAPEUTICS, INC. at $0.088 per Share, net in cash, plus one Contingent Value Right per share representing the contractual right to receive up to four contingent cash payments of up to an aggregate of $0.40 per CVR upon the achievement of specified Milestones plus the pro rata portion of any Clos |
|
| December 29, 2025 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 29, 2025 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of APPLIED THERAPEUTICS, INC. at $0.088 per share, net in cash, plus one non-tradable contingent value right (“CVR”) per share representing the contractual right to receive up to four contingent cash payments of up to an aggregate of $0.40 per CVR upon the achievement of certain specified milestones plus the p |
|
| December 29, 2025 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of APPLIED THERAPEUTICS, INC. at $0.088 per share, net in cash, plus one non-tradable contingent value right (“CVR”) per share representing the contractual right to receive up to four contingent cash payments of up to an aggregate of $0.40 per CVR upon the achievement of certain specified milestones plus the |
|
| December 29, 2025 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 20,492,304. |
|
| December 29, 2025 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Notice of Guaranteed Delivery With Respect to the Offer to Purchase All Outstanding Shares of Common Stock of APPLIED THERAPEUTICS, INC. at $0.088 PER SHARE, NET IN CASH, PLUS ONE NON-TRADABLE CONTINGENT VALUE RIGHT (“CVR”) PER SHARE REPRESENTING THE CONTRACTUAL RIGHT TO RECEIVE UP TO FOUR CONTINGENT CASH PAYMENTS OF UP TO AN AGGREGATE OF $0.40 PER CVR UPON THE AC |
|
| December 12, 2025 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Applied Therapeutics, Inc. (Name of Subject Company) Applied Therapeutics, Inc. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 03828A101 (CUSIP |
|
| December 12, 2025 |
EX-99.3 Exhibit 99.3 Dear Valued Partner, I just wanted to reach out and personally make you aware of the transaction we announced today given our strong existing partnership. We have reached an agreement to be acquired by Cycle Group Holdings Limited (“Cycle”), a company focused on providing treatments and services for patients with neurological, rare metabolic, and rare immunological conditions, |
|
| December 12, 2025 |
CONTINGENT VALUE RIGHTS AGREEMENT EX-2.2 Exhibit 2.2 Annex V FINAL FORM CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•] (this “Agreement”), is entered into by and between Cycle Group Holdings Limited, a private limited company incorporated in England and Wales (“Parent”), and [•], a [•], as Rights Agent (as defined herein). RECITALS WHEREAS, Parent, AT2B, Inc., a Delaware corporation and a |
|
| December 12, 2025 |
EX-99.5 Exhibit 99.5 Project Alpha – Master Q&A This document is intended for use by Applied senior leadership only, and not for broad distribution. General 1. Why does this transaction make sense for Applied? • After a thorough review of our options, the Board believes this transaction and the offer price is more favorable to the Company’s stockholders than the anticipated treatment of Shares in |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2025 Applied Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 12, 2025 |
EX-99.1 Exhibit 99.1 December 11, 2025 For Release: Immediately Cycle Pharmaceuticals to Acquire Applied Therapeutics Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 – Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmac |
|
| December 12, 2025 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among CYCLE GROUP HOLDINGS LIMITED, AT2B, INC. and APPLIED THERAPEUTICS, INC. Dated as of December 11, 2025 TABLE OF CONTENTS ARTICLE I THE OFFER 2 Section 1.1. The Offer 2 Section 1.2. Company Consent; Schedule 14D-9 4 Section 1.3. Stockholder Lists 4 ARTICLE II THE MERGER 5 Section 2.1. The Merger 5 Section 2.2. Closing; Effective |
|
| December 12, 2025 |
EX-99.1 Exhibit 99.1 December 11, 2025 For Release: Immediately Cycle Pharmaceuticals to Acquire Applied Therapeutics Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 – Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmac |
|
| December 12, 2025 |
EX-99.2 Exhibit 99.2 December 11, 2025 Applied Colleagues, Moments ago, we announced an agreement under which Cycle Group Holdings Limited (“Cycle”) will acquire Applied Therapeutics Inc. (“Applied”) for $0.088 per share in cash and one contingent value right (“CVR”) per share. Each CVR will entitle holders to potential milestone payments of up to $0.40 per share based on certain regulatory and co |
|
| December 12, 2025 |
EX-99.4 Exhibit 99.4 Subject: Applied Therapeutics to be Acquired by Cycle Group Holdings Hello, I’m reaching out to make sure you saw today’s announcement that Applied Therapeutics, Inc. (“Applied”) has entered into a definitive agreement to be acquired by Cycle Group Holdings Limited (“Cycle”), a leader in the development of treatments for neurological, rare metabolic, and rare immunological con |
|
| December 12, 2025 |
EX-10.1 Exhibit 10.1 Execution Version UNSECURED PROMISSORY NOTE December 11, 2025 FOR VALUE RECEIVED, Applied Therapeutics, Inc., a Delaware corporation (the “Company”), hereby promises to pay to Cycle Group Holdings Limited, a private limited company incorporated in England and Wales (the “Lender”), in lawful money of the United States and in immediately available funds, the principal sum of any |
|
| November 20, 2025 |
Applied Therapeutics Announces Corporate Updates Applied Therapeutics Announces Corporate Updates NEW YORK, November 20, 2025 – Applied Therapeutics, Inc. |
|
| November 20, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2025 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 13, 2025 |
Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2025 Financial Results - Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes - Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia - New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at th |
|
| November 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| August 29, 2025 |
Up to $75,000,000 Common Stock Applied Therapeutics, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-271887 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) Up to $75,000,000 Common Stock Applied Therapeutics, Inc. We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor, dated August 29, 2025, relating to the sale of shares of our common stock, par value $0.0001 p |
|
| August 29, 2025 |
Exhibit 10.1 Applied Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 29, 2025 Cantor Fitzgerald & Co. 110 E 59th Street New York, NY 10022 Ladies and Gentlemen: Applied Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follow |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 14, 2025 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2025 |
Applied Therapeutics Reports Second Quarter 2025 Financial Results - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT-SORD at PNS 2025 Annual Meeting highlighting slowed progression of disease observed via MRI at 24 months - Launched new sponsored Sorbitol Assay to support identification of patients suspected of having CMT-SORD - Entered into out-licensing agreement with Biossil, Inc. |
|
| August 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| August 12, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 17, 2025 |
APPLIED THERAPEUTICS INC. Evan Bailey, MD June 13, 2025 Dear Evan: This Amended and Restated Offer Letter (the “Letter Agreement”) confirms the terms and conditions of your employment at Applied Therapeutics Inc. (the “Company”) effective June 15, 2025 (the “Effective Date”). This Letter Agreement amends, restates, and supersedes the offer letter between you and the Company signed on March 15, 202 |
|
| June 17, 2025 |
Applied Therapeutics Announces Key Leadership Appointments - Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhD - Dottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs NEW YORK, June 17, 2025 - Applied Therapeutics, Inc. |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 17, 2025 |
Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL June 13, 2025 Riccardo Perfetti Dear Riccardo: This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation from employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to together |
|
| June 12, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| May 14, 2025 |
Employment Agreement, by and between the Registrant and Todd Baumgartner, dated March 7, 2025. Exhibit 10.1 APPLIED THERAPEUTICS INC. Todd Baumgartner March 7, 2025 Dear Todd: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the “Start Date”). 1. |
|
| May 13, 2025 |
Applied Therapeutics Reports First Quarter 2025 Financial Results - Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting - Review of govorestat development programs for Classic Galactosemia and CMT-SORD Deficiency ongoing NEW YORK, May 13, 2025 – Applied Therapeutics, Inc. |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 28, 2025 |
APPLIED THERAPEUTICS, INC. 2024 ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co |
|
| April 28, 2025 |
DEFA14A U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2025 |
Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 24, 2025 |
As filed with the Securities and Exchange Commission on April 24, 2025 As filed with the Securities and Exchange Commission on April 24, 2025 Registration No. |
|
| April 24, 2025 |
Exhibit 99.2 APPLIED THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE Applied Therapeutics, Inc. (the “Company”) hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. Although the Option is not granted pursuant to the Company’s 2019 Equity Incentive Plan (the “Plan”), for purposes of giving it meaning and interpreting its terms, the Opt |
|
| April 24, 2025 |
Exhibit 99.1 APPLIED THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE Applied Therapeutics, Inc. (the “Company”) hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). Although the Award is not made pursuant to the Company’s 2019 Equity Incentive Plan (the “Plan”), for purposes |
|
| April 24, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Applied Therapeutics, Inc. |
|
| April 18, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| April 15, 2025 |
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - Appointed John H. |
|
| April 15, 2025 |
Exhibit 19.1 Applied Therapeutics, Inc. Insider Trading Policy I. Introduction During the course of your relationship with Applied Therapeutics, Inc. (the “Company”), you may receive material information that is not yet public (“material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships. Material nonpublic informati |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388 |
|
| March 31, 2025 |
NT 10-K 1 aplt-fy24nt10-k3.28.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-38898 CUSIP NUMBER 03828A101 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 2 |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110246.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Applied Therapeutics, Inc. and further agree that th |
|
| February 14, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p25-0496exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of fi |
|
| February 10, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 7, 2025 |
EX-99.2 OPIN COUNSEL 3 EXHIBITNO.99.2.txt EXHIBIT NO. 99.2 ITEM 7 INFORMATION CUSIP No.03828A101 13G - EXHIBIT NO. 99.2 - ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley Capital Services LLC, a wholly-owned subsidiary of Morgan Stanley. |
|
| February 7, 2025 |
EX-99.1 CHARTER 2 EXHIBITNO.99.1.txt EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT CUSIP No.03828A101 13G - EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT - February 07, 2025 - MORGAN STANLEY and Morgan Stanley Capital Services LLC hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara - Ch |
|
| February 5, 2025 |
POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg and Brenda Schulz |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 Aperio Group, LLC BlackRock Advisors, LLC BlackRock Asset Management Canada Limited BlackRock Investment Management (Australia) Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns |
|
| February 3, 2025 |
EX-99.2 OPIN COUNSEL 3 EXHIBITNO.99.2.txt EXHIBIT NO. 99.2 ITEM 7 INFORMATION CUSIP No.03828A101 13G - EXHIBIT NO. 99.2 - ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley Capital Services LLC, a wholly-owned subsidiary of Morgan Stanley. |
|
| February 3, 2025 |
EX-99.1 CHARTER 2 EXHIBITNO.99.1.txt EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT CUSIP No.03828A101 13G - EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT - February 03, 2025 - MORGAN STANLEY and Morgan Stanley Capital Services LLC hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara - Ch |
|
| December 20, 2024 |
Offer Letter, between John H. Johnson and Applied Therapeutics, Inc., dated as of December 19, 2024 Exhibit 10.1 APPLIED THERAPEUTICS INC. John H. Johnson December 19, 2024 Dear John: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the “Start Date”). |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38898 (Commission File |
|
| December 20, 2024 |
Exhibit 10.2 APPLIED THERAPEUTICS INC. LETTER AMENDMENT TO OFFER LETTER December 19, 2024 Dear Les: This letter amendment (this “Letter Amendment”) modifies certain provisions set forth in that certain Offer Letter by and between Applied Therapeutics Inc. (the “Company”) and you, dated as of November 17, 2023 (the “Offer Letter”) in connection with your appointment as interim Chief Executive Offic |
|
| December 20, 2024 |
Exhibit 10.3 Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL December 19, 2024 Shoshana Shendelman c/o Jonathan S. Sack, Esq. Sack & Sack, Attorneys at Law 70 East 55th Street, 10th Floor New York, NY 10022 Dear Shoshana: This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separa |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2024 |
SC 13G/A 1 p24-3221sc13ga.htm APPLIED THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this sta |
|
| November 14, 2024 |
SC 13G/A 1 tm2428137d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State |
|
| November 14, 2024 |
APLT / Applied Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d911992dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A 101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statem |
|
| November 14, 2024 |
APLT / Applied Therapeutics, Inc. / JANUS HENDERSON GROUP PLC - JANUS AMENDMENT Passive Investment SC 13G/A 1 Applied093024.txt JANUS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: APPLIED THERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 03828A101 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designat |
|
| November 14, 2024 |
APLT / Applied Therapeutics, Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G/A 1 alyeska-aplt093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 13, 2024 |
SC 13G/A 1 tm2428198d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 6) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Stateme |
|
| November 8, 2024 |
APLT / Applied Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us03828a1016110824.txt us03828a1016110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) APPLIED THERAPEUTICS INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03828A101 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| November 7, 2024 |
Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2024 Financial Results - NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for govorestat for the treatment of SORD Deficiency under Accelerated Approval expected in early Q1 2025 NEW YO |
|
| November 6, 2024 |
APLT / Applied Therapeutics, Inc. / MORGAN STANLEY - MS INITIAL Passive Investment SC 13G 1 AppliedTherapAPTL.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Applied Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03828A101 - (CUSIP Number) September 30, 2024 - (Date Of Event which Requires Filing of this Statement) Check the appropri |
|
| October 24, 2024 |
APLT / Applied Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us03828a1016102424.txt us03828a1016102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) APPLIED THERAPEUTICS INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03828A101 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| August 14, 2024 |
APLT / Applied Therapeutics, Inc. / Shendelman Shoshana - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 9) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| August 7, 2024 |
2019 Equity Incentive Plan, as amended. Exhibit 10.5 APPLIED THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 24, 2019 APPROVED BY THE STOCKHOLDERS: APRIL 26, 2019 IPO DATE: MAY 13, 2019 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Applied Therapeutics, Inc. 2016 Equity Incentive Plan, as amended from time to time (the |
|
| August 7, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the “Corporation”), hereby certifies that: FIRST: |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2024 |
Amended and Restated Certificate of Incorporation of the Registrant, as amended. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware, hereby certifies that: 1: The original name of this corporation was Applied Therapeutics, Inc. and the date of filing the original Certificate of Incorporation of |
|
| August 7, 2024 |
Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2024 Financial Results - NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1 2025 - FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) Meeting to discuss NDA for govorestat for th |
|
| June 6, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
Exhibit 99.1 Applied Therapeutics Reports First Quarter 2024 Financial Results - Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 - Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025 - Company discussing potential NDA submission under Accelerated Approval for govorestat for |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
2019 Equity Incentive Plan, as amended. Exhibit 10.5 APPLIED THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 24, 2019 APPROVED BY THE STOCKHOLDERS: APRIL 26, 2019 IPO DATE: MAY 13, 2019 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Applied Therapeutics, Inc. 2016 Equity Incentive Plan, as amended from time to time (the |
|
| April 25, 2024 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-278182 Prospectus Applied Therapeutics, Inc. Up to 14,285,714 Shares of Common Stock For Resale Offered by the Selling Stockholders This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders” on page 7 of up to 14,285,714 s |
|
| April 23, 2024 |
Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 April 23, 2024 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Tim Buchmiller Re: Applied Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-278182) Request for Acceleration of Effective Date Ladies and Gentlemen: We r |
|
| April 22, 2024 |
TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38898 Applied Therape |
|
| April 22, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 15, 2024 |
Employment letter, by and between Applied Therapeutics, Inc. and Dale Hooks, dated April 9, 2024 Exhibit 10.1 EXECUTION VERSION APPLIED THERAPEUTICS INC. Dale Hooks April 9, 2024 Dear Dale: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the “Star |
|
| April 15, 2024 |
Separation agreement and general release, by and between Applied Therapeutics, Inc. and Adam Hansard Exhibit 10.2 Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL April 5, 2024 Adam Hansard Dear Adam: This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation of employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to togethe |
|
| April 11, 2024 |
TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 27, 2024 |
United States securities and exchange commission logo March 27, 2024 Shoshana Shendelman, Ph. |
|
| March 22, 2024 |
As filed with the Securities and Exchange Commission on March 22, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 22, 2024 Registration No. |
|
| March 22, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) APPLIED THERAPEUTICS, INC. |
|
| March 11, 2024 |
Exhibit 99.1 Applied Therapeutics March 2024 Various statements in this presentation concerning the Company’s future expectations, plans and prospects constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other simil |
|
| March 11, 2024 |
Exhibit 99.2 Applied Therapeutics SORD 12 Month Interim Data Analysis March 2024 Various statements in this presentation concerning the Company’s future expectations, plans and prospects constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” t |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: APPLIED THERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 03828A101 Date of Event Which Requires Filing of this Statement: 3/1/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388 |
|
| March 6, 2024 |
Exhibit 99.1 Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results - NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 - Announced positive results from 12-month interim analysis of govorestat in ongoing INSPIRE Pha |
|
| March 6, 2024 |
Applied Therapeutics, Inc. Clawback Policy Exhibit 97.1 APPLIED THERAPEUTICS, INC. CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Applied Therapeutics, Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 8) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon |
|
| February 29, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of February 27, 2024, by and among Applied Therapeutics, Inc., a Delaware corporation, with headquarters located at 545 Fifth Avenue, Suite 1400, New York, NY 10017 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Bu |
|
| February 29, 2024 |
Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES L |
|
| February 29, 2024 |
Exhibit 99.1 Applied Therapeutics Announces $100 Million Private Placement Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2026 NEW YORK, February 28, 2024 – Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage |
|
| February 29, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 27, 2024, by and among Applied Therapeutics, Inc., a Delaware corporation, with principal office located at 545 Fifth Avenue, Suite 1400, New York, New York 10017 (the "Company") and the undersigned buyers, (each, a "Buyer" and, collectively, the "Buyers"). WHEREAS: A. Pursuant to t |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 22, 2024 |
APLT / Applied Therapeutics, Inc. / Propel Bio Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 applied-therapeuticssc13ga1.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 2/9/2024 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2024 |
SC 13G/A 1 tm246235d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme |
|
| February 14, 2024 |
EX-99.1 2 d518545dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
APLT / Applied Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Passive Investment SC 13G/A 1 ss3005716sc13ga.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stat |
|
| February 14, 2024 |
APLT / Applied Therapeutics, Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G/A 1 alyeska-aplt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2024 |
SC 13G/A 1 tm245429d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 5) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statemen |
|
| February 14, 2024 |
APLT / Applied Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-aplt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2024 |
APLT / Applied Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d518545dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A 101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme |
|
| February 13, 2024 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0811exhibit99.htm JOINT ACQUISITION STATEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity o |
|
| February 13, 2024 |
SC 13G 1 p24-0811sc13g.htm APPLIED THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) |
|
| February 9, 2024 |
APLT / Applied Therapeutics, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.1 APPLIED THERAPEUTICS INC COMMON STOCK Cusip #03828A101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #03828A101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,427,436 Item 6: 0 Item 7: 2,427,436 Item 8: 0 Item 9: 2,427,436 Item 1 |
|
| February 6, 2024 |
APLT / Applied Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment appl23a41.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of |
|
| January 31, 2024 |
United States securities and exchange commission logo January 31, 2024 Shoshana Shendelman President and Chief Executive Officer Applied Therapeutics Inc. |
|
| January 25, 2024 |
APLT SEC Comment Letter Response – Advanz APLT SEC Comment Letter Response – Advanz Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 ( December 28, 2023) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of |
|
| December 29, 2023 |
Exhibit 10.1 APPLIED THERAPEUTICS INC. Constantine Chinoporos December 28, 2023 Dear Constantine: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the |
|
| December 21, 2023 |
December 21, 2023 BY EDGAR Division of Corporate Finance Office of Life Sciences U. |
|
| December 11, 2023 |
APLT / Applied Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment appli23a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) November 30, 2023 (Date of |
|
| December 7, 2023 |
United States securities and exchange commission logo December 7, 2023 Shoshana Shendelman President and Chief Executive Officer Applied Therapeutics Inc. |
|
| December 6, 2023 |
APLT / Applied Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d35458dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A 101 (CUSIP Number) December 4, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 17, 2023 |
Exhibit 10.1 APPLIED THERAPEUTICS INC. Les Funtleyder November 17, 2023 Dear Les: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company. Your anticipated start date is November 20, or a date to be mutually agreed upon (such actual date of y |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 ( November 16, 2023) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of |
|
| November 13, 2023 |
APLT / Applied Therapeutics Inc / Shendelman Shoshana - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 7) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon |
|
| November 9, 2023 |
Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2023 Financial Results Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023 Two Upcoming Phase 3 Trial Readouts, with ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy on track for data readout in 4Q 2023 and INSPIRE Trial of AT-007 trial in Sorbitol Deh |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| October 13, 2023 |
Exhibit 4.1 [THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES |
|
| October 13, 2023 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 13, 2023 |
Exhibit 10.1 October 12, 2023 Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 Re: Warrant Exchange Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of Applied Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to w |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 11, 2023 |
Up to $75,000,000 Common Stock Applied Therapeutics, Inc. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-271887 PROSPECTUS SUPPLEMENT (To prospectus dated May 19, 2023) Up to $75,000,000 Common Stock Applied Therapeutics, Inc. We have entered into a sales agreement with Leerink Partners LLC, or Leerink Partners, dated August 11, 2023, or the sales agreement, relating to the shares of our common stock, par value $0.0001 per shar |
|
| August 11, 2023 |
Sales Agreement, dated August 11, 2023, by and between the Company and Leerink Partners LLC. Exhibit 1.1 Applied Therapeutics, Inc. Up to $75,000,000 of Common Stock ($0.0001 par value) Sales Agreement August 11, 2023 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Applied Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Leerink Par |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 10, 2023 |
Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2023 Financial Results Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application planned in Fall 2023 Phase 3 INSPIRE Trial of govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Tria |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 (June 6, 2023) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporati |
|
| May 19, 2023 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-271887 Prospectus Applied Therapeutics, Inc. $300,000,000 Common Stock Preferred Stock Depositary Shares Debt Securities Warrants Offered by Applied Therapeutics, Inc. Up to 38,250,000 Shares of Common Stock Issuable upon Exercise of Warrants Up to 31,735,731 Shares of Common Stock for Resale Offered by the Selling Stockhold |
|
| May 17, 2023 |
Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 CORRESP 1 filename1.htm Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 May 17, 2023 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Tim Buchmiller Re: Applied Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-271887) Request for Acceleration of Effective Date Ladi |
|
| May 17, 2023 |
United States securities and exchange commission logo May 17, 2023 Shoshana Shendelman, Ph. |
|
| May 12, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) APPLIED THERAPEUTICS, INC. |
|
| May 12, 2023 |
As filed with the Securities and Exchange Commission on May 12, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 12, 2023 |
Exhibit 4.3 APPLIED THERAPEUTICS, INC. INDENTURE Dated as of , 20 DEBT SECURITIES , as Trustee Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310(a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 § 311 11.01(f), 16.02 § 312 14.02(d), 16.02 (b) 11.10,16.02 (c) 11.10,16.02 § 313(a) 10.01(a), 16 |
|
| May 11, 2023 |
Exhibit 99.1 Applied Therapeutics Reports First Quarter 2023 Financial Results Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement of Equity Phase 3 INSPIRE Trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy on Track for Data in 2023 |
|
| May 11, 2023 |
AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT NUMBER Applied Therapeutics, Inc. Amendment Date: , 2022 Reference is made to the above captioned Common Stock Purchase Warrant (the “Original Warrant”) that entitles the holder thereof and identified in the signatures pages hereto (the “Holder”), upon the terms and subject to the limitations on exercise and the conditions set forth in therein, at a |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| May 10, 2023 |
APLT / Applied Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment appl23a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) April 30, 2023 (Date of Even |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) April 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 2, 2023 |
APLT / Applied Therapeutics Inc / Propel Bio Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 2/28/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 6) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 27, 2023 |
Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES L |
|
| April 24, 2023 |
Exhibit 99.1 Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission · Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker data · Govorestat treatment improved a |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 24, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of April 23, 2023, by and among Applied Therapeutics, Inc., a Delaware corporation, with headquarters located at 545 Fifth Avenue, Suite 1400, New York, NY 10017 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyer |
|
| April 24, 2023 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES L |
|
| April 24, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of April 23, 2023, by and among Applied Therapeutics, Inc., a Delaware corporation, with principal office located at 545 Fifth Avenue, Suite 1400, New York, New York 10017 (the "Company") and the undersigned buyers, (each, a "Buyer" and, collectively, the "Buyers"). WHEREAS: A. Pursuant to the Sec |
|
| April 24, 2023 |
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity Exhibit 99.3 Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has entered into a |
|
| April 24, 2023 |
Exhibit 99.2 ACTION-Galactosemia Kids (AT-007-1002) Clinical Trial Update April 24, 2023 Disclaimer The information contained herein is strictly confidential and is being provided to you solely for your information and to assist you in making your own evaluation of Applied Therapeutics, Inc. (the “Company”). For the purposes of this disclaimer, the presentation includes all statements made orally |
|
| April 17, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 17, 2023 |
definitive proxy statement on Schedule 14A, filed with the SEC on April 17, 2023; TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38898 Applied Therape |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 31, 2023 |
APLT / Applied Therapeutics Inc / Propel Bio Partners L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 10/27/2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| March 23, 2023 |
Amended and Restated Certificate of Incorporation of the Registrant, as amended. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware, hereby certifies that: 1:The original name of this corporation was Applied Therapeutics, Inc. and the date of filing the original Certificate of Incorporation of |
|
| March 23, 2023 |
EX-10.9 4 aplt-20221231xex10d9.htm EX-10.9 Exhibit 10.9 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between APPLIED THERAPEUTICS, INC. and M |
|
| March 23, 2023 |
EX-99.1 2 tm2310080d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, Including Positive Sorbitol Reduction Data from the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency On Track to Report Additional Phase 3 Data Across Multiple Progra |
|
| March 23, 2023 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF APPLIED THERAPEUTICS, INC. (A DELAWARE CORPORATION) March 16, 2021 Table of Contents Page ARTICLE I OFFICES1 Section 1. Registered Office1 Section 2. Other Offices1 ARTICLE II CORPORATE SEAL1 Section 3. Corporate Seal1 ARTICLE III STOCKHOLDERS’ MEETINGS1 Section 4. Place of Meetings1 Section 5. Annual Meetings.1 Section 6. Special Meetings.5 Sect |
|
| March 23, 2023 |
As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. |
|
| March 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Applied Therapeutics, Inc. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388 |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2023 |
APLT / Applied Therapeutics Inc / Propel Bio Partners L.P. - SC 13G Passive Investment SC 13G 1 applied-therapeuticssc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 10/27/2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2023 |
APLT / Applied Therapeutics Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
APLT / Applied Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 ss1758554sc13ga.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat |
|
| February 14, 2023 |
SC 13G/A 1 a021323a.htm SCHEDULE 13G (AMENDMENT NO. 1) 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Applied Therapeutics, Inc. (Ti |
|
| February 14, 2023 |
APLT / Applied Therapeutics Inc / Alyeska Investment Group, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2023 |
APLT / Applied Therapeutics Inc / FMR LLC Passive Investment SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 APPLIED THERAPEUTICS INC COMMON STOCK Cusip #03828A101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #03828A101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,972,371 Item 6: 0 Item 7: 2,972,371 Item 8: 0 Item |
|
| January 30, 2023 |
APLT / Applied Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment appl22in1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2022 (Date of E |
|
| January 23, 2023 |
APLT / Applied Therapeutics Inc / Knoll Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Applied Therapeutics Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) |
|
| January 4, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| November 9, 2022 |
Applied Therapeutics Reports Third Quarter 2022 Financial Results Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2022 Financial Results NEW YORK, November 9, 2022 - Applied Therapeutics, Inc. (NASDAQ: APLT) (the ?Company?), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended Sep |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 28, 2022 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the ?Corporation?), hereby certifies that: FIRST: |
|
| October 14, 2022 |
SC 13D/A 1 sc13da.htm SCHEDULE 13D, AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment. No. 5) APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth |
|
| September 9, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| September 9, 2022 |
TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted b |
|
| August 26, 2022 |
TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by |
|
| August 12, 2022 |
Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2022 Financial Results Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2H 2022, inclu |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc. |
|
| August 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss |
